Literature DB >> 21498914

The occurrence of neonatal acute respiratory disorders in 21-hydroxylase deficiency.

Keisuke Nagasaki1, Tadashi Asami, Yuki Abe, Touhei Usuda, Toru Kikuchi, Makoto Uchiyama.   

Abstract

Patients with 21-hydroxyase deficiency (21-OHD) usually do not present clinical symptoms other than female ambiguous genitalia and skin pigmentation at birth. However, we have found a case of neonatal transient tachypnea with spontaneous pneumomediastinum in a neonate with 21-OHD at birth. The purpose of this study was to investigate the occurrence of neonatal respiratory disorders in 21-OHD patients. From April 1989 to March 2009, 478,337 Japanese newborns were screened for congenital adrenal hyperplasia in Niigata prefecture. Among these newborns, 26 patients were diagnosed as having 21-OHD. We investigated the presence of neonatal respiratory disorders based on the retrospective medical records of 24 full-term patients with 21-OHD. Three of the 24 patients (12.5%) had neonatal acute respiratory disorders. Neonatal transient tachypnea developed in all patients with only oxygenation for two or three days after birth. Chest X-rays showed spontaneous pneumothorax or pneumomediastinum in two patients. In conclusion, 21-OHD patients may present with acute respiratory disorders, especially transient tachypnea with spontaneous pneumothorax, at birth. In cases of delivering mothers having other children with 21-OHD, newborns require attention regarding neonatal respiratory disorders if a prenatal diagnosis has not been performed. ©The Japan Endocrine Society

Entities:  

Mesh:

Year:  2011        PMID: 21498914     DOI: 10.1507/endocrj.k11e-036

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  1 in total

1.  Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study.

Authors:  Atsumi Tsuji; Kaoru Konishi; Satomi Hasegawa; Akira Anazawa; Toshikazu Onishi; Makoto Ono; Tomohiro Morio; Teruo Kitagawa; Kenichi Kashimada
Journal:  BMC Pediatr       Date:  2015-12-15       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.